Skip to main content

Table 1 Patient characteristics at the time of [68Ga]Ga-PSMA-11 scan

From: Gallium-68 prostate-specific membrane antigen ([68Ga]Ga-PSMA-11) PET for imaging of thyroid cancer: a feasibility study

Patient #

Age

Sex

Thyro-globulin (ng/mL); Ab +/−

TSH (mIU/ L)

Tumor type

Years since diagnosis

Treatment history

Years Since RAI; EBRT

I-123/131 uptake on most recent scan?

Months to PSMA PET

1

78

M

17; −

0.36

PTC

14

S, RAIx1, EBRT

6; 1

No

3.0

2

58

F

520.2; +

0.01

HCC

5

S, RAIx2, EBRT

3; 1

No

1.8

3

80

M

22.0; −

0.11

PDPTC

28

S

n/a; n/a

No

2.4

4

79

M

245.1; +

2.7

ATC

< 1

S

n/a; n/a

Unknown

0.4

5

72

F

1771.0; −

n/a

FTC

5

S, RAIx2

4; n/a

No

1.8

6

65

F

2125.8;−

0.01

PDPTC

3

S, EBRT

n/a; 1

No

3.0

7

66

F

7.3; −

0.11

PTC

3

S, RAIx1, EBRT

3; 3

No

5.3

8

46

F

0.1; −

12.1

ATC

< 1

S, RAIx1

0.5; n/a

No

1.2

9

62

M

0.1; + 

0.37

PTC

2

S, RAIx2

1; n/a

No

0.7

10

47

F

20,540.0; −

0.01

FTC

< 1

S

n/a; n/a

Yes*

11.4

11

54

M

15.6; −

0.13

HCC

8

S, RAIx3, EBRT

4; 2

Unknown

1.5

  1. Time to PSMA PET: months from most recent 2-[18F]FDG PET or [123I]Iodide/[131I]Iodide scan to [68Ga]Ga-PSMA-11 PET
  2. Ab anti-thyroglobulin antibodies, TSH thyroid stimulating hormone, PTC papillary thyroid carcinoma, HCC Hurthle cell carcinoma, PDPTC poorly differentiated papillary thyroid carcinoma, ATC anaplastic thyroid carcinoma, FTC follicular thyroid carcinoma, S surgery, RAI radioactive iodine therapy, EBRT external beam radiation therapy, Chemo chemotherapy
  3. *Patient 10 was planned for RAI which was performed approximately 1 month after imaging workup (including PSMA PET)